Assays used in conjunction with a thermal contrast reader are disclosed. In the assay, the test strip includes materials that can develop a thermal response if a target analyte is present in a sample. Linear flow assays include nanoparticles with high affinity binding to the analyte. Binding of the nanoparticles with an analyte in the sample is detected using thermal contrast. Analytes over a broad range of concentrations are detected in the linear flow assays. Methods of detecting target analytes and kits comprising lateral flow assays and thermal contrast reader are also disclosed.

The present disclosure relates to the field of medical technology, which provides methods and apparatuses for identifying red blood cells infected by plasmodium. The methods may include: obtaining a forward-scattered light signal, a side-scattered light signal and an optional fluorescence signal from cells in a blood sample; obtaining a first two-dimensional scattergram according to the forward-scattered light signal and the side-scattered light signal, or obtaining a three-dimensional scattergram according to the forward-scattered light signal, the side-scattered light signal and the fluorescence signal; and identifying cells located in a predetermined area of the first two-dimensional scattergram or the three-dimensional scattergram as the red blood cells infected by plasmodium. The apparatuses perform the methods. The methods and apparatuses can have better identification accuracy.

The present disclosure relates to the field of medical technology, which provides methods and apparatuses for identifying red blood cells infected by plasmodium. The methods may include: obtaining a forward-scattered light signal, a side-scattered light signal and an optional fluorescence signal from cells in a blood sample; obtaining a first two-dimensional scattergram according to the forward-scattered light signal and the side-scattered light signal, or obtaining a three-dimensional scattergram according to the forward-scattered light signal, the side-scattered light signal and the fluorescence signal; and identifying cells located in a predetermined area of the first two-dimensional scattergram or the three-dimensional scattergram as the red blood cells infected by plasmodium. The apparatuses perform the methods. The methods and apparatuses can have better identification accuracy.

The present invention, in at least some embodiments, is of a system, method, apparatus and diagnostic test for monitoring infections by Plasmodium falciparum that is specific for pregnant women. The monitoring is performed by examining samples from the pregnant women, typically blood samples, for the presence of antibodies to a known P. falciparum protein, VAR2CSA. Preferably, the antibodies bind specifically to p5 and/or p8.

The invention relates to a test system comprising at least one of the following means: permeabilising means (110) and/or lysis of at least one pathogen (10) and/or at least one cell (10), means for capturing (80) and/or making (90) parts (20 and/or 40 and/or 50) of the pathogens (10) and/or cells (10), means for localising, immobilising and/or enriching (120) at least one component (40 and/or 50 and/or 20 and/or 10) of a pathogen (10) and/or a cell (10), means for image processing (160) preferably comprising an optical magnifying unit (161), enabling an optical reading out of at least one means for localising, immobilising and/or enriching (120) can be carried out.

The present invention relates to a vaccine V comprising (A) at least one isolated polypeptide strand P comprising or consisting of at least nine consecutive amino acid moieties of the repetitive organellar protein, putative of Plasmodium falciparum or the hypothetical protein PVNG_04523 of Plasmodium vivax or a polynucleotide strand encoding for such polypeptide; and (B) at least one pharmaceutically acceptable carrier or excipient. Furthermore, the present invention refers to an antibody binding to the repetitive organellar protein,putative of Plasmodium falciparumor the hypothetical protein PVNG_04523 of Plasmodium vivax or a polynucleotide strand encoding therefor, to a method of generating such antibody and uses thereof.

The present invention relates to biomarker sensors with a multielectrode array structure, kits containing them, methods for their production as well as corresponding uses and applications.

The invention provides a bioactive peptide including a partial amino acid sequence of Plasmodium falciparum enolase, and having a molecular structure compatible with a specification setting for a GMP-compliant production process. The peptide has a structure in which two peptides, each having an amino acid sequence of A01-Ala-Ser-Glu-Phe-Tyr-Asn-Ser-Glu-Asn-Lys-Thr-Tyr-Asp-Leu-Asp-Phe-Lys-Thr-Pro-Asn-Asn-Asp-A02 (SEQ ID NO: 1) or A03-Ala-Ser-Glu-Phe-Tyr-Asn-Ser-Glu-Asn-Lys-Thr-Tyr-Asp-Leu-Asp-Phe-Lys-Thr-Pro-Asn-Asn-Asp-Lys-Ser-Leu-Val-Lys-Thr-A04 (SEQ ID NO: 2) are linked by amide bonds between the respective carboxy termini of the two peptides and two amino groups of Lys in a linker peptide represented by Lys-A05-Cys-A06 and arranged in the form of a two-forked branch, wherein each of A01 to A06 represents an amino acid residue in a number of an arbitrary number including 0. The peptide preferably has a dimerized structure in which two of the above described peptides are linked by an SS bond between the Cys residues in the linker peptide sequences included in the respective two peptides.

The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Provided herein is also a concentrator and a kit for use with the methods.

A method for detecting a malaria infection whereby providing a mouth cleansing product to a user then asking the user to blow or breathe onto or into a capture mechanism, wherein the capture mechanism may contain a thioether detection mechanism such as Michler's Hydrol; and analyzing whether a thioether detection mechanism displays any loss of the thioether detection mechanism. The invention also discloses a kit for indicating the presence of malaria by instructing the user to exhale through a capture mechanism after using a mouth cleansing product, wherein the kit includes a thioether detection mechanism such as Michler's Hydrol.